Search and analyze individual stocks with comprehensive metrics
Wockhardt Ltd
Fundamental Score
Wockhardt Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of WOCKPHARMA across key market metrics for learning purposes.
Positive Indicators
1 factors identified
Robust Profit Growth (454.55%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Risk Factors
11 factors identified
Below-Average Return on Equity (-1.22%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (3.75%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Premium Valuation Risk (P/E: 436.52x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
Limited Growth History (1.15% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities. Assess future growth catalysts.
Weak Interest Coverage (1.37x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability. Monitor cash flow and debt reduction plans.
Negative Free Cash Flow (₹-535.25 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
High Share Pledging Risk (21.30%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns or margin calls.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Very Low ROE
Observation: Poor capital utilization and shareholder returns.
Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Very High P/E Ratio
Observation: Significant overvaluation risk present.
Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.
Loading Peer Comparison
Finding companies in the Pharmaceuticals sector...
Financial Statements
Comprehensive financial data for Wockhardt Ltd
About WOCKPHARMA
Business Overview
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Company Details
Key Leadership
Corporate Events
WOCKPHARMA Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Wockhardt Ltd (WOCKPHARMA)?
As of 19 Jan 2026, 10:10 am IST, Wockhardt Ltd (WOCKPHARMA) is currently trading at ₹1417.60. The stock has a market capitalization of ₹23.95K (Cr).
Is WOCKPHARMA share price Overvalued or Undervalued?
WOCKPHARMA is currently trading at a P/E ratio of 436.52x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the Wockhardt Ltd share price?
Key factors influencing WOCKPHARMA's price include its quarterly earnings growth (Sales Growth: -3.34%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Wockhardt Ltd a good stock for long-term investment?
Wockhardt Ltd shows a 5-year Profit Growth of 11.37% and an ROE of -1.22%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.54 before investing.
How does Wockhardt Ltd compare with its industry peers?
Wockhardt Ltd competes with major peers in the Pharmaceuticals. Investors should compare WOCKPHARMA's P/E of 436.52x and ROE of -1.22% against the industry averages to determine its competitive standing.
What is the P/E ratio of WOCKPHARMA and what does it mean?
WOCKPHARMA has a P/E ratio of 436.52x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹437 for every ₹1 of annual earnings.
How is WOCKPHARMA performing according to Bull Run's analysis?
WOCKPHARMA has a Bull Run fundamental score of 12.1/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does WOCKPHARMA belong to?
WOCKPHARMA operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Wockhardt Ltd.
What is Return on Equity (ROE) and why is it important for WOCKPHARMA?
WOCKPHARMA has an ROE of -1.22%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Wockhardt Ltd generates profits from shareholders' equity.
How is WOCKPHARMA's debt-to-equity ratio and what does it indicate?
WOCKPHARMA has a debt-to-equity ratio of 0.54, which indicates moderate leverage that should be monitored. A ratio below 1.0 generally indicates conservative financing.
What is WOCKPHARMA's dividend yield and is it a good dividend stock?
WOCKPHARMA offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has WOCKPHARMA grown over the past 5 years?
WOCKPHARMA has achieved 5-year growth rates of: Sales Growth 1.15%, Profit Growth 11.37%, and EPS Growth 11.79%.
What is the promoter holding in WOCKPHARMA and why does it matter?
Promoters hold 49.08% of WOCKPHARMA shares, with 21.30% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is WOCKPHARMA's market capitalization category?
WOCKPHARMA has a market capitalization of ₹23950 crores, placing it in the Large-cap category.
How volatile is WOCKPHARMA stock?
WOCKPHARMA has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for WOCKPHARMA?
WOCKPHARMA has a 52-week high of ₹N/A and low of ₹N/A.
What is WOCKPHARMA's operating profit margin trend?
WOCKPHARMA has a 5-year average Operating Profit Margin (OPM) of 5.69%, indicating the company's operational efficiency.
How is WOCKPHARMA's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of -3.34% and YoY Profit Growth of 454.55%.
What is the institutional holding pattern in WOCKPHARMA?
WOCKPHARMA has FII holding of 7.10% and DII holding of 11.00%. Significant institutional holding often suggests professional confidence in the stock.